Skip to main content
. 2019 Mar 12;43(5):2133–2143. doi: 10.3892/ijmm.2019.4131

Figure 8.

Figure 8

Effects of LY294002 (PI3K/Akt inhibitor) on the protection of MRF against H/R-stimulated cell death and apoptosis. (A) Effects of MRF and LY on cell viability in H/R-treated cardiomyocytes. (B) Effects of MRF and LY on ROS levels in H/R-treated cardiomyocytes. The intracellular ROS levels were measured with a fluorometric assay. (C) Representative western blot analysis of the protein expression levels of p-Akt, Akt, p-GSK-3β, GSK-3β, Bcl-2 and Bax in cardiomyocytes. (D) The ratios of p-Akt/Akt, p-GSK3β/GSK-3β and Bcl-2/Bax were represented in bar graph. β-actin expression was examined as the protein loading control. The data are expressed as the mean ± standard deviation from three independent experiments. #P<0.05 vs. the control, ##P<0.01 vs. the control; *P<0.05 vs. the H/R-treated cells, **P<0.01 vs. the H/R-treated cells. *P<0.05 vs. H/R+MRF-treated cells and **P<0.01 vs. the H/R+MRF-treated cells. MRF, Myrica rubra flavonoids; H/R, hypoxia/reoxygenation; Akt, protein kinase B; p-GSK-3β, phosphorylated glycogen synthase kinase 3β; LY, LY294002; ROS, reactive oxygen species; PI3K, phosphoinositide 3 kinase.